Chemotherapeutic drugs induced female reproductive toxicity and treatment strategies

Abstract

Increase in success of cancer treatment with advancement in the screening, prognosis and diagnosis protocols have significantly improved the rate of cancer survivorship. With the declining cancer mortality, however, the cancer survivors are also subjected to the adverse consequences of chemotherapy, particularly in the female reproductive system. Recent studies have shown the sensitivity of the ovarian tissue to the chemotherapeutic drugs‐induced toxicity. Several in vitro and in vivo studies have assessed the toxic effects of chemotherapeutic drugs. The most frequently used chemotherapeutic drugs such as doxorubicin, cyclophosphamide, cisplatin and paclitaxel have been reported to cause ovarian damage, diminution of follicular pool reserve, premature ovarian failure and early menopause, resulting into declining fertility potential among females. The chemotherapy often employs combination of drug regimen to increase the efficacy of the treatment. However, the literature mostly consists of clinical data regarding the gonadotoxicity caused by anticancer drugs but there lacks the understanding of toxicity mechanism. Therefore, understanding of the different toxicity mechanisms will be helpful in development of possible therapeutic interventions for preservation of declining female fertility among cancer survivors. The current review comprehends the underlying mechanisms of female reproductive toxicity induced by the most commonly used chemotherapeutic drugs. In addition, the review also summarizes the recent findings related to the use of various protectants to diminish or at least in managing the toxicity induced by different chemotherapeutic drugs in females.

Ovarian function in patients with systemic lupus erythematosus: Pathogenesis, drug application and prospective therapies

“…Moreover, CTX-induced ovarian toxicity may be mediated by an inflammatory response, which can be caused by increasing the levels of proinflammatory cytokines [interleukin (IL)-6, IL-8, TNFα, etc. ] and decreasing the levels of anti-inflammatory factors such as IL-10[ 17 ]. In addition, CTX changes the expression of pro- and antiapoptotic genes, leading to increased apoptosis in the ovary[ 18 ].…”

Progress in the study of reproductive toxicity of platinum-based antitumor drugs and their means of prevention

“…However, it also potentially damages normal cells ( Oun et al, 2018 ; Ben Ayed et al, 2020 ) and impacts healthcare workers exposed to them for a prolonged duration via skin and respiratory tract ( Lehmann and Williams, 2020 ). Cisplatin is one of the treatments known for its adverse effects on systemic organs such as the uterus and ovaries ( Albayrak et al, 2021 ; Bhardwaj et al, 2023 ), leading to ovarian endocrine disruption, follicular growth and developmental disorders, as well as liver and kidney function damage ( Pabla and Dong, 2008 ; Gong et al, 2021 ). Consequently, it is crucial to investigate the mechanism behind cisplatin’s toxic effects and develop strategies to protect occupational health against antitumor active platinum compounds.…”

Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

“…At present, many cytotoxic drugs with different killing mechanisms have been successfully developed to maximize the therapeutic effect on diseases. Chemotherapeutic drugs such as vincristine, camptothecin (CPT), and paclitaxel (PTX) have significant growth inhibitory effects on a variety of common tumor cells, but their inability to distinguish normal cells from diseased cells leads to an untargeted tissue distribution and general toxicity . Thus, systemic chemotherapy frequently leads to severe side effects, impacting not only the immediate well-being, quality of life, and mental health of cancer patients but also indirectly influencing the intensity and continuity of the treatment.…”